Logo image of IMMP

IMMUTEP LTD-SP ADR (IMMP) Stock Fundamental Analysis

USA - NASDAQ:IMMP - US45257L1089 - ADR

1.7 USD
+0.05 (+3.03%)
Last: 11/7/2025, 1:36:32 PM
Fundamental Rating

3

Taking everything into account, IMMP scores 3 out of 10 in our fundamental rating. IMMP was compared to 534 industry peers in the Biotechnology industry. While IMMP seems to be doing ok healthwise, there are quite some concerns on its profitability. IMMP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

IMMP had negative earnings in the past year.
In the past year IMMP has reported a negative cash flow from operations.
In the past 5 years IMMP always reported negative net income.
In the past 5 years IMMP always reported negative operating cash flow.
IMMP Yearly Net Income VS EBIT VS OCF VS FCFIMMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

The Return On Assets of IMMP (-24.06%) is better than 73.97% of its industry peers.
IMMP's Return On Equity of -25.43% is amongst the best of the industry. IMMP outperforms 80.52% of its industry peers.
Industry RankSector Rank
ROA -24.06%
ROE -25.43%
ROIC N/A
ROA(3y)-29.13%
ROA(5y)-31.07%
ROE(3y)-31.51%
ROE(5y)-33.92%
ROIC(3y)N/A
ROIC(5y)N/A
IMMP Yearly ROA, ROE, ROICIMMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMMP Yearly Profit, Operating, Gross MarginsIMMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20K -40K -60K -80K -100K

6

2. Health

2.1 Basic Checks

IMMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMMP has less shares outstanding
Compared to 5 years ago, IMMP has more shares outstanding
The debt/assets ratio for IMMP is higher compared to a year ago.
IMMP Yearly Shares OutstandingIMMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
IMMP Yearly Total Debt VS Total AssetsIMMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

IMMP has an Altman-Z score of 19.59. This indicates that IMMP is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of IMMP (19.59) is better than 89.89% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that IMMP is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, IMMP is in line with its industry, outperforming 47.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.59
ROIC/WACCN/A
WACC8.9%
IMMP Yearly LT Debt VS Equity VS FCFIMMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 18.86 indicates that IMMP has no problem at all paying its short term obligations.
The Current ratio of IMMP (18.86) is better than 93.63% of its industry peers.
A Quick Ratio of 18.86 indicates that IMMP has no problem at all paying its short term obligations.
The Quick ratio of IMMP (18.86) is better than 93.63% of its industry peers.
Industry RankSector Rank
Current Ratio 18.86
Quick Ratio 18.86
IMMP Yearly Current Assets VS Current LiabilitesIMMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

4

3. Growth

3.1 Past

IMMP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.43%.
The Revenue for IMMP has decreased by -49.75% in the past year. This is quite bad
The Revenue for IMMP have been decreasing by -66.35% on average. This is quite bad
EPS 1Y (TTM)-14.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.44%
Revenue 1Y (TTM)-49.75%
Revenue growth 3Y-38.18%
Revenue growth 5Y-66.35%
Sales Q2Q%-18.07%

3.2 Future

The Earnings Per Share is expected to grow by 75.20% on average over the next years. This is a very strong growth
Based on estimates for the next years, IMMP will show a very strong growth in Revenue. The Revenue will grow by 123.43% on average per year.
EPS Next Y-25.63%
EPS Next 2Y-11.81%
EPS Next 3Y25.84%
EPS Next 5Y75.2%
Revenue Next Year1.99%
Revenue Next 2Y-27.58%
Revenue Next 3Y180.85%
Revenue Next 5Y123.43%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IMMP Yearly Revenue VS EstimatesIMMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
IMMP Yearly EPS VS EstimatesIMMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 -6

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMMP. In the last year negative earnings were reported.
Also next year IMMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMMP Price Earnings VS Forward Price EarningsIMMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMMP Per share dataIMMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as IMMP's earnings are expected to grow with 25.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.81%
EPS Next 3Y25.84%

0

5. Dividend

5.1 Amount

IMMP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

IMMUTEP LTD-SP ADR

NASDAQ:IMMP (11/7/2025, 1:36:32 PM)

1.7

+0.05 (+3.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-29 2025-08-29/bmo
Earnings (Next)02-24 2026-02-24
Inst Owners40.58%
Inst Owner Change0.08%
Ins Owners2.13%
Ins Owner ChangeN/A
Market Cap247.28M
Revenue(TTM)60.10K
Net Income(TTM)-43.87M
Analysts82.22
Price Target2.59 (52.35%)
Short Float %3.09%
Short Ratio33.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.3%
PT rev (3m)14.46%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-15.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)25.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7052.74
P/FCF N/A
P/OCF N/A
P/B 2.2
P/tB 2.3
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0
BVpS0.77
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.06%
ROE -25.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.13%
ROA(5y)-31.07%
ROE(3y)-31.51%
ROE(5y)-33.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 1556.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.86
Quick Ratio 18.86
Altman-Z 19.59
F-Score2
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.44%
EPS Next Y-25.63%
EPS Next 2Y-11.81%
EPS Next 3Y25.84%
EPS Next 5Y75.2%
Revenue 1Y (TTM)-49.75%
Revenue growth 3Y-38.18%
Revenue growth 5Y-66.35%
Sales Q2Q%-18.07%
Revenue Next Year1.99%
Revenue Next 2Y-27.58%
Revenue Next 3Y180.85%
Revenue Next 5Y123.43%
EBIT growth 1Y-12.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.65%
EBIT Next 3Y34.14%
EBIT Next 5Y19.8%
FCF growth 1Y-10.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.95%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUTEP LTD-SP ADR / IMMP FAQ

What is the ChartMill fundamental rating of IMMUTEP LTD-SP ADR (IMMP) stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMMP.


What is the valuation status for IMMP stock?

ChartMill assigns a valuation rating of 1 / 10 to IMMUTEP LTD-SP ADR (IMMP). This can be considered as Overvalued.


How profitable is IMMUTEP LTD-SP ADR (IMMP) stock?

IMMUTEP LTD-SP ADR (IMMP) has a profitability rating of 1 / 10.


What is the financial health of IMMUTEP LTD-SP ADR (IMMP) stock?

The financial health rating of IMMUTEP LTD-SP ADR (IMMP) is 6 / 10.